Company profile
Revolo Biotherapeutics | Analyze. Reset. Revolutionize.
Revolo Biotherapeutics is a revolutionary biotherapeutics company on a mission to revolutionize autoimmune and allergic disease treatment by resetting the immune system for long-term disease remission
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MzA0MDY4NGFkaXF6a2N4
Published 13 Nov 2024 10:46
SH01 | Transaction MzQzNDY1ODI0OGFkaXF6a2N4
Published 05 Sep 2024 15:31
Company registered at Companies House
1 Jun 2018 to 31 Mar 2019
"Peptinnovate is a clinical stage biotechnology company based at the Stevenage Bioscience Catalyst. The company's core research is based on molecules derived from Mycobacterium tuberculosis proteins, as innovative immunomodulatory agents for the treatment of chronic inflammatory diseases. The lead molecule PIN201104 is a safe, low molecular weight peptide...
1 Jan 2017 to 31 Mar 2018
Peptinnovate is a drug discovery and development company based in the Stevenage Bioscience Catalyst on the GSK site. The company's core research is based on molecules derived from Mycobacterium tuberculosis proteins as innovative immunomodulatory agents for the treatment of chronic inflammatory diseases. The lead molecule PIN201104 is an extremely safe, l...
1 Sep 2015 to 31 Aug 2016
Peptinnovate have discovered that proteins derived from mycobacterium tuberculosis (mTB) unexpectedly act as potent anti-inflammatory agents both in vivo (animal) and in vitro (human and animal), via an unknown mechanism of action. Peptide fragments of the mTB protein have been successfully synthesised and shown to have equivalent or augmented activity in...
1 Aug 2015 to 31 Jul 2016
Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they have evolved over millennia to remain hidden in the body by producing proteins that modulate the host's immune system. These proteins have been shown to interact with and reduce the body's natural inflammatory processes. Peptinnovate’s innovation Peptinnovate’s approach is t...
1 Jan 2015 to 31 Mar 2016
Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they have evolved over millennia to remain hidden in the body by producing proteins that modulate the host's immune system. These proteins have been shown to interact with and reduce the body's natural inflammatory processes. Peptinnovate’s innovation Peptinnovate’s approach is t...
1 Dec 2013 to 30 Nov 2014
Tuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolved over 1000’s of years to remain hidden in the body by producing proteins that modulate the host's immune system. These proteins have been shown to interact with and reduce the body's natural inflammatory processes. Peptinnovate’s innovation Peptinnovate’s approach...
1 Mar 2013 to 30 Nov 2013
Tuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolved over millenia to remain hidden in the body by producing proteins that subvert the host's immune system by interacting with the body's natural inflammatory processes. Peptinnovate’s innovative approach is to unlock the anti-inflammatory activity of these proteins ...
1 Jun 2012 to 30 Nov 2013
Tuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolved over 1000’s of years to remain hidden in the body by producing proteins that modulate the host's immune system. These chaperonin proteins have been shown to interact with and reduce the body's natural inflammatory process. Peptinnovate’s innovation: Peptinnovate’...
